XORTX Therapeutics Inc.

2:00 PM - 2:15 PM (PDT), Monday, June 13, 2022
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.
Ticker:
XRTX
Exchange:
NADAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Alberta
Company HQ Country:
Canada
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
XRx-008
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO and President
XORTX Therapeutics